Skip to main
KOD
KOD logo

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 44%
Buy 0%
Hold 38%
Sell 6%
Strong Sell 13%

Bulls say

Kodiak Sciences Inc's potential for stock growth is underpinned by its promising product candidate KSI-301, which aims to treat prevalent retinal diseases and has shown advancements in delivery methods, reducing dosing times significantly in ongoing Phase 3 trials. The company’s tarcocimab has exhibited strong durability, with encouraging results reported from pivotal trials such as GLOW1 and BEACON, indicating non-inferiority against standard treatments, and supporting future prospects in diabetic retinopathy and retinal vein occlusion. As the retinal disease therapy landscape evolves with competitive options, Kodiak's ability to demonstrate differentiated efficacy and safety in the upcoming GLOW2 and DAYBREAK trials will be crucial for solidifying its market position and enhancing investor confidence.

Bears say

Kodiak Sciences Inc faces significant risks that contribute to a negative outlook on its stock, primarily stemming from the unsuccessful Phase 3 trials of its product candidate, tarcocimab, which resulted in an unexpected increase in cataract adverse events. The company reported a substantial net loss of $43.9 million for the third quarter of 2024, raising concerns about its ability to secure sufficient capital resources to fund ongoing operations and program development. Additionally, the challenges associated with the previous tarcocimab formulation, including prolonged delivery time and potential adverse effects, further complicate the investment thesis by casting doubt on the commercial viability of its developmental candidates.

KOD has been analyzed by 16 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 6% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 16 analysts, KOD has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.